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410a Tuesday, February 28, 2012more rigorous physical model combined with effective sampling of molecular
configurations is critical for binding affinity prediction to chemical accuracy,
which is defined as within one order of magnitude of the true equilibrium dis-
sociation constant. We have demonstrated that electrostatic interactions, espe-
cially electronic polarization, are critical for protein-ligand recognition due to
the significant change in electrostatic environments between bulk water and
protein pockets and have achieved encouraging success in treating charged spe-
cies using the polarizable Atomic Multipole Optimized Energetics for Biomo-
lecular Applications (AMOEBA) force field. To maintain accuracy while also
achieving efficiency, AMOEBA has been combined with the Orthogonal Space
Random Walk en-
hanced alchemical
free energy algo-
rithm. Here we pres-
ent applications of
this strategy for the
computation of pro-
tein-ligand binding
affinities and, for the
first time, drug solu-
bility from alchemi-
cal simulations using
the Force Field X
software.2083-Plat
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Many ion channels such as the MloK1 channel are steered by ligand binding via
conformational changes. Mainly two binding mechanisms have been proposed,
induced fit and conformational selection. Using molecular dynamics simula-
tions, we studied ligand binding of cyclic adeonise monophosphate at the cyclic
nucleotide binding domain of the MloK1 ion channel of Mesorizobium loti. For
this binding domain, both crystal and NMR structures have been determined for
both the ligand free as well as for the ligand bound conformation.
In the simulations, spontaneous binding was observed, which enabled us to de-
termine reaction coordinates for the ligand binding as well as for the associated
conformational change of the protein. We used a combination of force probe
simulations, umbrella sampling, and unbiased simulations to determine poten-
tials of mean force along these reaction coordinates, transition rates, as well as
free energy differences and barriers between the most relevant substates.
Our results are compared with measured affinities and kinetics, and suggest an
induced fit-mechanism.
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How drugs bind to their receptors—from initial association, through entry into
the binding pocket, to adoption of the final bound pose—has remained un-
known, even for G-protein-coupled receptor modulators, which constitute
one-third of all drugs. We captured this pharmaceutically critical process in
atomic detail using the first unbiased molecular dynamics simulations in which
drug molecules spontaneously associate with G-protein-coupled receptors to
achieve final poses matching those determined crystallographically (PNAS
108:13118 (2011)). We found that several beta blockers and a beta agonist
all traverse the same dominant pathway as they bind to the b1- and b2-adrener-
gic receptors, initially associating with a vestibule on
each receptor’s extracellular surface. Surprisingly, this
association, at a distance of 15 A˚ from the binding
pocket, often presents the largest energetic barrier to
binding, despite the fact that subsequent entry into the
pocket requires the receptor to deform and the drug to
squeeze through a narrow passage. The early barrier
may reflect the substantial dehydration that occurs as
the drug associates with the vestibule. Our atomic-level
description of the binding process suggests opportunities
for allosteric modulation and provides a structural foun-
dation for future optimization of binding and unbinding
rates.2085-Plat
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The active components of animal venoms are potentially useful in many elec-
trophysiological and pharmacological applications due to their highly selective
nature. Of this rich concoction, the binding mechanisms of many toxin types
remain to be elucidated. We therefore present a preliminary method to deduce
the selectivity profile of a peptide toxin against related channels by means of
docking simulations. This is tested on the family of a-KTx scorpion toxins,
for which structural and limited affinity data are available for over 20 toxins
across seven sub-families. Docking simulations against Kv1.1, Kv1.2 and
Kv1.3 were carried out under both blind-docking trials and common-lysine-
motif trials, using the program HADDOCK.
This study reports on a selection of toxins for which validation can be best pro-
vided, given current limitations of docking accuracy. The general selectivity
profiles of toxin-subfamilies can be deduced via consensus between closely re-
lated toxin-channel pairings. In particular, HADDOCK was able to classify
a-KTX2 toxins as universal binders and a-KTX3 toxins as Kv1.3-selective
binders. An estima-
tion of individual se-
lectivity profiles can
be further deduced by
program performance.
This method is ex-
pected to be useful in
the refinement of
toxins for channel-
subtype targetting.2086-Plat
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Virus ion channels are small (3-15 kD) peptides that aggregate to form ion
channels that are important for viral infection1. As viruses continue to pose
a major worldwide health problem, these ion channels represent an exciting
new target for therapeutic intervention. Viral ion channels that have been pre-
viously identified include Vpu of the human immunodeficiency virus (HIV) and
P7 of Hepatitis C however it is the M2 influenza A protein that represents the
best exploited ion channel drug target so far.
The proton-selective M2 ion channel is the target of the adamantane family of
drug inhibitors. Use of the two most common adamantane inhibitors, amanta-
dine and rimantadine have declined steadily over recent years due to the emer-
gence of adamantane-resistant flu strains. We have conducted a series of
surface plasmon resonance experiments designed to measure the affinity be-
tween several ion channel inhibitors and M22. By examining drug binding to
a number of mutant M2 constructs (derived from adamantane-resistant strains),
it was possible to establish the location of the drug binding sites and to ratio-
nalise the effect on drug binding of specific mutant residues. In light of these
results, the prospect for future development of a new generation of M2 inhib-
itors will be discussed. Moreover, we explore the possibility of expanding this
field of research to incorporate ion channel proteins from other viruses.
1. Gonzalez, M and Carrasco, L (2003). FEBS Lett. (2003) 552(1):28-34.
2. Rosenberg, M and Casarotto, M (2010) PNAS 107(31):13866-71.
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Small molecule kinase inhibitors have recently demonstrated dramatic po-
tential for treating cancers caused by dysregulated protein kinases. The ef-
ficacy of these compounds is due to their ability to selectively target
particular protein kinases, and this selectivity is remarkable given the fact
that they bind to the ATP-binding site of the kinase domain, which is highly
conserved in sequence across this large protein family. The origin of this
selectivity is unknown, but must relate to differences in physical properties
of the ATP-binding site among members of this protein family. The goal of
this project is to assess how the evolutionary divergence of sequence and
structure in the human kinome translates into variation in ATP-binding
site electrostatics, and how this variation can be exploited to design highly
selective inhibitors. I am using a clinically important class of kinase
